6:42 PM
 | 
Nov 10, 2008
 |  BC Extra  |  Clinical News

Optimer reports Phase III CDAD data

Late Monday, Optimer (NASDAQ:OPTR) released top-line data from a Phase III trial of OPT-80 to treat Clostridium difficile-associated diarrhea (CDAD) showing non-inferiority to Vancocin vancomycin on the primary...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >